Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 108.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,159 shares of the company's stock after purchasing an additional 36,565 shares during the period. Wealth Enhancement Advisory Services LLC owned 0.06% of Apellis Pharmaceuticals worth $1,534,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its stake in Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after acquiring an additional 758 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after purchasing an additional 918 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at about $83,000. US Bancorp DE grew its stake in Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after buying an additional 1,327 shares during the last quarter. Finally, Covestor Ltd grew its stake in Apellis Pharmaceuticals by 1,819.2% during the 4th quarter. Covestor Ltd now owns 3,992 shares of the company's stock worth $127,000 after buying an additional 3,784 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company's stock.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS traded up $0.56 during mid-day trading on Tuesday, hitting $17.87. 2,896,342 shares of the company's stock traded hands, compared to its average volume of 2,344,706. The firm's 50 day simple moving average is $18.12 and its 200 day simple moving average is $23.90. The company has a market cap of $2.25 billion, a PE ratio of -9.98 and a beta of 0.68. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $42.47. The company has a debt-to-equity ratio of 2.76, a quick ratio of 3.62 and a current ratio of 4.08.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The company had revenue of $149.90 million for the quarter, compared to analyst estimates of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The company's revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.54) earnings per share. Sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on APLS shares. Cantor Fitzgerald started coverage on Apellis Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $44.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Robert W. Baird reduced their price objective on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. The Goldman Sachs Group reduced their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Finally, Bank of America downgraded Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price target for the company from $41.00 to $23.00 in a research note on Friday, May 9th. Nine investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $40.05.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $18.77, for a total transaction of $93,850.00. Following the sale, the general counsel owned 133,730 shares of the company's stock, valued at $2,510,112.10. This trade represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.50% of the stock is currently owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).